Skip to main content
  • Home
  • Malaysia In Focus - ARNI Data And Its Implications On Clinical Practice

Malaysia In Focus - ARNI Data And Its Implications On Clinical Practice

Topic:
  • Heart Failure

Available Credit:

  • 1.00 MMA

Course Published On:

Course Expiry Date:

Overview

This on-demand programme, Malaysia In Focus - ARNI Data And Its Implications On Clinical Practice, has been developed to further education among practicing cardiologists to ensure understanding of the latest ARNI data in HFpEF and HFrEF, how emerging data relates to current practice in Malaysia, and is intended to support the application of current understanding of ARNI therapy in appropriate heart failure patients.

 

The programme brings together a leading international faculty from Malaysian, US, Germany, Singapore, for a four-part series, featuring eight videos.

 

This programme accredited by the Malaysian Medical Association (MMA) for 1 external CPD credit. Once the course is completed, there are instructions on how to receive your credit.

Disclosure

In compliance with Malaysian Medical Association (MMA) guidelines, all speakers/chairpersons participating in this programme have disclosed or indicated potential conflicts of interest which might cause a bias in the presentations.

 

The Organising Committee/Course Director is responsible for ensuring that all potential conflicts of interest relevant to the event are declared to the audience prior to the CPD activities.

 

This programme is supported by an unrestricted educational grant from Novartis. The scientific programme has not been influenced in any way by the sponsor.

Terms & Conditions

Radcliffe Education requires contributors to our CME/CPD programmes to disclose any relevant financial relationships that have occurred within the past 12 months that could create a conflict of interest. These will be identified in the faculty section if applicable.

 

This programme ‘Malaysia In Focus - ARNI Data And Its Implications On Clinical Practice’ is accredited by the Malaysian Medical Association (MMA)  for 1 hour of external CPD credits.

 

Each participant should claim only those hours of credit that have actually been spent in the educational activity.

Instructions to Participants

There is no fee for taking part in this online learning activity.

 

Physicians should only claim credits for time spent on the activity. To successfully earn credit, participants must complete the activity in full in the indicated time frame.

 

To complete the course and claim certification participants must:

  • Read the course outline information supplied and complete pre-test questions if supplied prior to starting the activity. Users must read and study the activity in its entirety before completing the post-test questions.
  • Your results will be automatically saved and if a pass score is achieved (where applicable), you may be eligible to claim credit for the activity and receive a certificate of completion.

Learning Objectives

  • Understand the latest ARNI data in HFpEF and HFrEF
  • Understand how emerging data relates to current practice in Malaysia
  • Apply current understanding of ARNI therapy in appropriate heart failure patients
Register now Log in

Module

Title

Duration

Speakers

1 Meet the Expert Presentation – Local Interpretation of Emerging ARNI Data in HF Carolyn Lam (National Heart Centre Singapore Duke-NUS, Singapore) Wan Azman Wan Ahmad (University of Malaya Medical Centre, Kuala Lumpur, Malaysia)
2 Meet the Expert Q&A – Local Interpretation of Emerging ARNI Data in HF Carolyn Lam (National Heart Centre Singapore Duke-NUS, Singapore) Wan Azman Wan Ahmad (University of Malaya Medical Centre, Kuala Lumpur, Malaysia)
3 Interview – Managing Hypotension in Patients with HFrEF (Utilising ARNIs) Carolyn Lam (National Heart Centre Singapore Duke-NUS, Singapore)
4a Clinical questions on ARNI therapy – Chapter 1: Local Interpretation of Emerging ARNI Data in HF Azmee Mohd Ghazi (National Heart Institute, Kuala Lumpur, Malaysia)
4b Clinical questions on ARNI therapy – Chapter 2: ARNI Therapy Mode of Action James Januzzi (Massachusetts General Hospital, US) Akshay Desai (Brigham and Women’s Hospital, Boston, MA, US) Azmee Mohd Ghazi (National Heart Institute, Kuala Lumpur, Malaysia)
4c Clinical questions on ARNI therapy – Chapter 3: Safety and Efficacy of ARNI Therapy in Acute Heart Failure Azmee Mohd Ghazi (National Heart Institute, Kuala Lumpur, Malaysia) David Morrow (Brigham and Women’s Hospital, US)
4d Clinical questions on ARNI therapy – Chapter 4: When to Initiate ARNI Therapy in Acute Heart Failure Azmee Mohd Ghazi (National Heart Institute, Kuala Lumpur, Malaysia) Rolf Wachter (University of Leipzig, Leipzig, Germany)
4e Clinical questions on ARNI therapy – Chapter 5: Summary Azmee Mohd Ghazi (National Heart Institute, Kuala Lumpur, Malaysia)
1.

Meet the Expert Presentation – Local Interpretation of Emerging ARNI Data in HF

Duration:

Speakers: Carolyn Lam (National Heart Centre Singapore Duke-NUS, Singapore) Wan Azman Wan Ahmad (University of Malaya Medical Centre, Kuala Lumpur, Malaysia)

3.

Interview – Managing Hypotension in Patients with HFrEF (Utilising ARNIs)

Duration:

Speakers: Carolyn Lam (National Heart Centre Singapore Duke-NUS, Singapore)

4a.

Clinical questions on ARNI therapy – Chapter 1: Local Interpretation of Emerging ARNI Data in HF

Duration:

Speakers: Azmee Mohd Ghazi (National Heart Institute, Kuala Lumpur, Malaysia)

4c.

Clinical questions on ARNI therapy – Chapter 3: Safety and Efficacy of ARNI Therapy in Acute Heart Failure

Duration:

Speakers: Azmee Mohd Ghazi (National Heart Institute, Kuala Lumpur, Malaysia) David Morrow (Brigham and Women’s Hospital, US)

4d.

Clinical questions on ARNI therapy – Chapter 4: When to Initiate ARNI Therapy in Acute Heart Failure

Duration:

Speakers: Azmee Mohd Ghazi (National Heart Institute, Kuala Lumpur, Malaysia) Rolf Wachter (University of Leipzig, Leipzig, Germany)

4e.

Clinical questions on ARNI therapy – Chapter 5: Summary

Duration:

Speakers: Azmee Mohd Ghazi (National Heart Institute, Kuala Lumpur, Malaysia)

Speaker

Wan Azman Wan Ahmad

Prof Wan Azman Wan Ahmad is Professor and Senior Consultant of Cardiologist at University of Malaya Medical Centre, Kuala Lumpur, Malaysia. He graduated from University of Malaya in 1983 and currently serves as President of the National Heart Association of Malaysia.

View full profile

Carolyn Lam

National Heart Centre Singapore Duke-NUS, Singapore, SG

Dr Carolyn Lam is a Senior Consultant of the National Heart Centre, Singapore and Professor of Duke-NUS Cardiovascular Academic Clinical Program. Dr Lam’s clinical sub-specialty is heart failure, and she is recognized globally for her expertise in heart failure with preserved ejection fraction.

View full profile

Azmee Mohd Ghazi

National Heart Institute, Kuala Lumpur, MY

Dr Azmee Mohd Ghazi is a Cardiologist at the National Heart Centre, Malaysia, where he serves as Clinical Director for Heart Failure and Heart Transplant.

View full profile

James Januzzi

Massachusetts General Hospital

Dr James L Januzzi,  is an Associate Professor of Medicine at Harvard Medical School and Director of the Cardiac Intensive Care Unit at Massachusetts General Hospital. He has an in-depht experience as a teacher and leads a research programme with specific focus on cardiac biomarker testing.

View full profile

Akshay Desai

Brigham and Women’s Hospital, Boston, MA, US

Prof Akshay Desai is a cardiovascular medicine specialist and the director of the Cardiomyopathy and Heart Failure Program at Brigham and Women’s Hospital. Dr Desai’s research focuses on improving care and outcomes for HF patients, as well as strategies to reduce heart failure readmissions. 

View full profile

David Morrow

Cardiovascular Division, Brisham and Women’s Hospital

Prof David A Morrow the Director of the Samuel A. Levine Cardiac Intensive Care Unit in the Division of Cardiovascular Medicine at Brigham and Women's Hospital and a Professor of Medicine at Harvard Medical School. He directs the TIMI Biomarker Program

View full profile

Rolf Wachter

University of Leipzig, Leipzig, Germany

Prof Rolf Wachter is Director of Cardiology at the Clinic and Policlinic for Cardiology, University Hospital Leipzig. Prior to this, he served as Deputy Director (Leitender Oberarzt), Clinic for Cardiology and Pneumology, University Medicine Göttingen, Germany.

View full profile

AVAILABLE CREDIT

1.00 Malaysian Medical Association (MMA)

Related Courses

SGLT-2 Inhibitors - Another Piece of the Puzzle in Heart Failure
  • 1 EBAC

Learning objectives

  • Recall the results of key trials in HFmrEF in different patients' sub-groups
  • Describe how SGLT-2 inhibitors can be used across the range of LVEF
  • Apply emerging diagnostic approaches for HFpEF and HFmrEF
  • Implement best-practice strategies across the range of LVEF
See more
Making Gains in HFpEF: An Appraisal of Where We Are Now

Learning objectives

  • Identify HFpEF patients who may benefit from being initiated on an SGLT-2 inhibitor
  • Recall current inertia rates amongst prescribers who manage heart failure
  • Adopt effective treatment strategies for HFpEF patients early in the disease course
  • Recall current guideline directed medical therapy options in HFpEF
  • Review clinical, real world and quality of life evidence for the use of SGLT-2 inhibitors in HFpEF
See more
Heart Failure Management in a Changing Paradigm
  • 1 EBAC

Learning objectives

  • Recall the utility of EF in heart failure treatment, patient selection and treatment response
  • Identify alternative measures to EF for the purposes HF severity and therapeutic efficacy
  • InIncorporate quality of life measures for assessing therapeutic efficacy in HF
  • Recall outcomes from heart failure trials from recent congress and publications and their impact on practice
See more
The 2022 ACC Heart Failure Guidelines: What Do They Mean for Your Practice?

Learning objectives

  • Summarise the main updates to the 2022 ACC heart failure (HF) guidelines
  • Compare updates from the ACC with the 2021 ESC HF guidelines
  • Recall guideline recommendations for the initiation of foundational therapy for heart failure
  • Adopt foundational GMDT early in the disease course
  • Postulate how ejection fraction will be used in future trials and in future guidelines
  • Review existing and forthcoming trial evidence on SGLT-2 inhibitors in HFpEF
See more
HFO 2022 - Session 3.3: Live Case & Discussion
  • 1.00 European Board for Accreditation of Continuing Education for Health Professionals (EBAC)

Learning objectives

  • Select foundational and advanced management strategies in complex patients
  • Discuss the validity of using ejection fraction to determine optimal treatment strategies
  • Assess the likely impact of health technology on future practice
  • Identify the underlying causes of heart failure
  • Select appropriate interventional and device-based treatments for treating underlying causes of heart failure
  • Assess the impact of the multidisciplinary team on heart failure outcomes
  • Discuss the importance of using quality of life and patient self-assessed measures relative to hard clinical end points
See more
HFO 2022 - Session 3.1 & 3.2: Quality of Life and Multi-disciplinary Care in HF
  • 1.00 European Board for Accreditation of Continuing Education for Health Professionals (EBAC)

Learning objectives

  • Select foundational and advanced management strategies in complex patients
  • Discuss the validity of using ejection fraction to determine optimal treatment strategies
  • Assess the likely impact of health technology on future practice
  • Identify the underlying causes of heart failure
  • Select appropriate interventional and device-based treatments for treating underlying causes of heart failure
  • Assess the impact of the multidisciplinary team on heart failure outcomes
  • Discuss the importance of using quality of life and patient self-assessed measures relative to hard clinical end points
See more
HFO 2022 - Session 2.5 Practical Theory & Hot Topics: Advanced HF Care
  • 1.00 European Board for Accreditation of Continuing Education for Health Professionals (EBAC)

Learning objectives

  • Select foundational and advanced management strategies in complex patients
  • Discuss the validity of using ejection fraction to determine optimal treatment strategies
  • Assess the likely impact of health technology on future practice
  • Identify the underlying causes of heart failure
  • Select appropriate interventional and device-based treatments for treating underlying causes of heart failure
  • Assess the impact of the multidisciplinary team on heart failure outcomes
  • Discuss the importance of using quality of life and patient self-assessed measures relative to hard clinical end points
See more
HFO 2022 - Session 2.3 Practical Theory & Hot Topics: HF Aetiology
  • 1.00 European Board for Accreditation of Continuing Education for Health Professionals (EBAC)

Learning objectives

  • Select foundational and advanced management strategies in complex patients
  • Discuss the validity of using ejection fraction to determine optimal treatment strategies
  • Assess the likely impact of health technology on future practice
  • Identify the underlying causes of heart failure
  • Select appropriate interventional and device-based treatments for treating underlying causes of heart failure
  • Assess the impact of the multidisciplinary team on heart failure outcomes
  • Discuss the importance of using quality of life and patient self-assessed measures relative to hard clinical end points
See more
HFO 2022 - Session 2.2 Live Case and Discussion
  • 1.00 European Board for Accreditation of Continuing Education for Health Professionals (EBAC)

Learning objectives

  • Select foundational and advanced management strategies in complex patients
  • Discuss the validity of using ejection fraction to determine optimal treatment strategies
  • Assess the likely impact of health technology on future practice
  • Identify the underlying causes of heart failure
  • Select appropriate interventional and device-based treatments for treating underlying causes of heart failure
  • Assess the impact of the multidisciplinary team on heart failure outcomes
  • Discuss the importance of using quality of life and patient self-assessed measures relative to hard clinical end points
See more
HFO 2022 - Session 1.4 Practical Theory & Hot Topics: Transitioning Care and Monitoring Technology
  • 1.00 European Board for Accreditation of Continuing Education for Health Professionals (EBAC)

Learning objectives

  • Select foundational and advanced management strategies in complex patients
  • Discuss the validity of using ejection fraction to determine optimal treatment strategies
  • Assess the likely impact of health technology on future practice
  • Identify the underlying causes of heart failure
  • Select appropriate interventional and device-based treatments for treating underlying causes of heart failure
  • Assess the impact of the multidisciplinary team on heart failure outcomes
  • Discuss the importance of using quality of life and patient self-assessed measures relative to hard clinical end points
See more